Qiang Wang

发表

Clinical application status and prospect of the combined anti-tumor strategy of ablation and immunotherapy

L. Yin, Guiyuan Chen, Li-Quan Yin, 2022, Frontiers in Immunology.

Pexidartinib versus placebo for advanced tenosynovial giant cell tumour (ENLIVEN): a randomised phase 3 trial

David M. Thomas, J. Blay, J. Desai, 2019, The Lancet.

Pexidartinib for advanced tenosynovial giant cell tumor: results of the randomized phase 3 ENLIVEN study

J. Blay, C. Peterfy, W. Tap, 2019 .

Pexidartinib Provides Modest Pain Relief in Patients With Tenosynovial Giant Cell Tumor: Results From ENLIVEN

J. Desai, R. Speck, W. Tap, 2022, Clinical orthopaedics and related research.

Dose-Ranging Study of the Safety and Pharmacokinetics of Atrasentan in Patients with Refractory Malignancies

M. Ratain, E. Vokes, C. Ryan, 2004, Clinical Cancer Research.

Retrospective analysis of LNM risk factors and the effect of chemotherapy in early colorectal cancer: A Chinese multicenter study

Jun Huang, Qingtian Luo, Youxiang Chen, 2020, BMC cancer.

Tivantinib in Combination with Erlotinib versus Erlotinib Alone for EGFR‐Mutant NSCLC: An Exploratory Analysis of the Phase 3 MARQUEE Study

G. Scagliotti, F. Shepherd, J. von Pawel, 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

First-in-human study of the antibody DR5 agonist DS-8273a in patients with advanced solid tumors

M. Maitland, J. Bendell, G. Senaldi, 2017, Investigational New Drugs.

Apatinib inhibits the growth of small cell lung cancer via a mechanism mediated by VEGF, PI3K/Akt and Ki‐67/CD31

N. Zhong, Wenjian Jin, Qiang Wang, 2021, Journal of cellular and molecular medicine.

A randomized, double-blind, placebo-controlled phase 2 study of tigatuzumab (CS-1008) in combination with carboplatin/paclitaxel in patients with chemotherapy-naïve metastatic/unresectable non-small cell lung cancer.

M. Krzakowski, J. von Pawel, R. Beckman, 2013, Lung cancer.

High dose radiation therapy based on normal tissue constraints with concurrent chemotherapy achieves promising survival of patients with unresectable stage III non-small cell lung cancer.

Jian Zhang, Baosheng Li, Zhong-tang Wang, 2019, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

Phase III Multinational, Randomized, Double-Blind, Placebo-Controlled Study of Tivantinib (ARQ 197) Plus Erlotinib Versus Erlotinib Alone in Previously Treated Patients With Locally Advanced or Metastatic Nonsquamous Non-Small-Cell Lung Cancer.

G. Scagliotti, L. Sequist, F. Shepherd, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Efficacy Analysis for Molecular Subgroups in MARQUEE: a Randomized, Double-blind, Placebo-controlled, Phase 3 Trial of Tivantinib (ARQ 197) Plus Erlotinib versus Placebo plus Erlotinib in Previously Treated Patients with Locally Advanced or Metastatic, Non-squamous, Non-small Cell Lung Cancer (NSCLC

G. Scagliotti, L. Sequist, F. Shepherd, 2014 .

Intensity-modulated radiotherapy for breast cancer: a systematic review

Kehu Yang, Q. Wang, Jinhui Tian, 2010 .

Safety and efficacy of tigatuzumab plus sorafenib as first-line therapy in subjects with advanced hepatocellular carcinoma: A phase 2 randomized study.

M. Kudo, N. Izumi, Yoon-Koo Kang, 2015, Journal of hepatology.

Phase 2, multicenter, open-label study of tigatuzumab (CS-1008), a humanized monoclonal antibody targeting death receptor 5, in combination with gemcitabine in chemotherapy-naive patients with unresectable or metastatic pancreatic cancer

L. Hart, J. Infante, R. Beckman, 2013, Cancer medicine.

Pexidartinib improves physical functioning and stiffness in patients with tenosynovial giant cell tumor: results from the ENLIVEN randomized clinical trial

J. Desai, R. Speck, W. Tap, 2021, Acta orthopaedica.

Efficacy and safety of immune checkpoint inhibitors with or without radiotherapy in metastatic non-small cell lung cancer: A systematic review and meta-analysis

Lihua Dong, Zijing Liu, Shouliang Gong, 2023, Frontiers in Pharmacology.

Long‐term outcomes of pexidartinib in tenosynovial giant cell tumors

J. Desai, C. Peterfy, W. Tap, 2020, Cancer.

Final results of ENLIVEN: A global, double-blind, randomized, placebo-controlled, phase 3 study of pexidartinib in advanced tenosynovial giant cell tumor (TGCT).

J. Blay, J. Desai, W. Tap, 2018 .

Modified cancer TNM classification for localized renal cell carcinoma based on the prognostic analysis of 3748 cases from a single center.

Ye Tian, Jian Zhang, Zhijia Liu, 2021, Canadian journal of physiology and pharmacology.

Pexidartinib Long‐Term Hepatic Safety Profile in Patients with Tenosynovial Giant Cell Tumors

W. Tap, J. Healey, H. Gelderblom, 2020, The Oncologist.

Phase III study of cisplatin with pemtrexed or vinorelbine plus concurrent late course accelerated hyperfractionated radiotherapy in patients with unresectable stage III non-small cell lung cancer

Jian Zhang, Baosheng Li, Zhong-tang Wang, 2016, Oncotarget.

Regional anesthesia did not improve postoperative long-term survival of tumor patients: a systematic review and meta-analysis of randomized controlled trials

Xian-qing Meng, Di Wang, Z. Dai, 2023, World Journal of Surgical Oncology.

Gene Mutation Analysis in Papillary Thyroid Carcinoma Using a Multi-Gene Panel in China

Ning Zhao, Qiang Wang, Jun Zhang, 2021, International journal of general medicine.

Pexidartinib for advanced tenosynovial giant cell tumor (TGCT): Long-term efficacy and safety from the phase 3 ENLIVEN and phase 1 PLX108-01 (TGCT cohort) studies.

J. Desai, C. Peterfy, W. Tap, 2019, Journal of Clinical Oncology.

Bronchial artery chemoembolization with apatinib for treatment of central lung squamous cell carcinoma

K. Lei, Yuming Jia, G. Xiao, 2022, Journal of cancer research and therapeutics.

Evaluation of Potential Drug‐Drug Interaction Risk of Pexidartinib With Substrates of Cytochrome P450 and P‐Glycoprotein

M. Gordon, H. Babiker, F. Kobayashi, 2020, Journal of clinical pharmacology.

Modified cancer TNM classification for localized renal cell carcinoma based on the prognostic analysis of 3748 cases from a single center.

Ye Tian, Jian Zhang, Zhijia Liu, 2020, Canadian journal of physiology and pharmacology.